Adverum Biotech
Patrick Machado is currently the Director at Adverum Biotech. Prior to this, they were with Xenon Pharmaceuticals Inc., Arcus Biosciences, and Principia Biopharma. At Principia Biopharma, they were a member of the Board of Directors and chaired the Audit Committee from June 2019 to September 2020. Before that, they were with Turning Point Therapeutics and Therachon, where they served as a member of the Board of Directors. Patrick has also been with Turnstone Biologics and Adverum Biotechnologies, Inc. in the past. Most recently, they were with Roivant Sciences. Patrick Machado began their career at Chimerix, Inc.
This person is not in the org chart
This person is not in any offices
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.